AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Lineage Cell Therapeutics Presents at H.C. Wainwright 27th Annual Global Investment Conference
ByAinvest
Saturday, Sep 13, 2025 1:46 am ET1min read
Lineage Cell Therapeutics presented at H.C. Wainwright's 27th Annual Global Investment Conference. The company's CEO, Brian Culley, discussed the company's mission to manufacture and deliver specific cell types to address diseases where cell loss causes the condition. The focus is on dry age-related macular degeneration, where RPE cells are lost, and the company manufactures RPE cells in the lab to restore function in patients. The pipeline includes other neurological and ophthalmic conditions.
Lineage Cell Therapeutics, Inc. has announced the initiation of a new islet cell transplant program for Type 1 Diabetes (T1D). The company aims to deploy its manufacturing capability to address the issue of large-scale production of islet cells, with the initial goal of establishing a production modality that can support the entire production process in a dynamic culturing system [1].The new program is a significant step towards commercializing islet cell therapy product candidates. Islet cell transplantation is a promising treatment for T1D, which affects millions of people worldwide. By manufacturing islet cells in a dynamic culturing system, Lineage Cell Therapeutics aims to overcome a major hurdle to the commercialization of this therapy.
The company's CEO, Brian Culley, presented at H.C. Wainwright's 27th Annual Global Investment Conference, discussing the company's mission to manufacture and deliver specific cell types to address diseases where cell loss causes the condition. The focus is on dry age-related macular degeneration, where retinal pigment epithelial (RPE) cells are lost, and the company manufactures RPE cells in the lab to restore function in patients [2].
The pipeline of Lineage Cell Therapeutics also includes other neurological and ophthalmic conditions. The company's commitment to innovation and addressing unmet medical needs positions it as a potential leader in cell-based therapies.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet